Viridian Therapeutics Inc
1S1
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
143
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,184.20 | 27.30 | -0.30% |
| CAC 40 | 8,310.84 | 20.12 | -0.24% |
| DAX 40 | 25,301.20 | 14.96 | 0.06% |
| Dow JONES (US) | 49,397.75 | 248.12 | 0.50% |
| FTSE 100 | 10,244.01 | 59.66 | 0.59% |
| HKSE | 26,923.62 | 76.19 | -0.28% |
| NASDAQ | 23,651.17 | 179.42 | 0.76% |
| Nikkei 225 | 54,110.50 | 230.73 | -0.42% |
| NZX 50 Index | 13,659.79 | 97.92 | -0.71% |
| S&P 500 | 6,963.89 | 37.29 | 0.54% |
| S&P/ASX 200 | 8,861.70 | 19.30 | -0.22% |
| SSE Composite Index | 4,112.60 | 13.49 | -0.33% |